Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000950170-25-053321
Filing Date
2025-04-11
Accepted
2025-04-11 16:43:54
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 14860
2 EX-99.1 ck0001669811-ex99_1.pdf EX-99.1 367044
  Complete submission text file 0000950170-25-053321.txt   522331
Mailing Address 7 BD HAUSSMANN PARIS I0 75009
Business Address 7 BD HAUSSMANN PARIS I0 75009 01 53 83 09 63
Abivax S.A. (Subject) CIK: 0001956827 (see all company filings)

EIN.: 000000000 | State of Incorp.: I0 | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-94198 | Film No.: 25832745
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address THE INVUS GROUP, LLC 750 LEXINGTON AVENUE, 30TH FLOOR NEW YORK NY 10022
Business Address THE INVUS GROUP, LLC 750 LEXINGTON AVENUE, 30TH FLOOR NEW YORK NY 10022 212-371-1717
Invus Global Management, LLC (Filed by) CIK: 0002005369 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G